GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CSPC Pharmaceutical Group Ltd (STU:CVG) » Definitions » Current Ratio

CSPC Pharmaceutical Group (STU:CVG) Current Ratio : 2.54 (As of Jun. 2024)


View and export this data going back to . Start your Free Trial

What is CSPC Pharmaceutical Group Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. CSPC Pharmaceutical Group's current ratio for the quarter that ended in Jun. 2024 was 2.54.

CSPC Pharmaceutical Group has a current ratio of 2.54. It generally indicates good short-term financial strength.

The historical rank and industry rank for CSPC Pharmaceutical Group's Current Ratio or its related term are showing as below:

STU:CVG' s Current Ratio Range Over the Past 10 Years
Min: 1.83   Med: 2.2   Max: 2.81
Current: 2.54

During the past 13 years, CSPC Pharmaceutical Group's highest Current Ratio was 2.81. The lowest was 1.83. And the median was 2.20.

STU:CVG's Current Ratio is ranked better than
61.45% of 1035 companies
in the Drug Manufacturers industry
Industry Median: 1.97 vs STU:CVG: 2.54

CSPC Pharmaceutical Group Current Ratio Historical Data

The historical data trend for CSPC Pharmaceutical Group's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSPC Pharmaceutical Group Current Ratio Chart

CSPC Pharmaceutical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.20 2.53 2.81 2.67 2.63

CSPC Pharmaceutical Group Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 2.63 - 2.54 -

Competitive Comparison of CSPC Pharmaceutical Group's Current Ratio

For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CSPC Pharmaceutical Group's Current Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's Current Ratio distribution charts can be found below:

* The bar in red indicates where CSPC Pharmaceutical Group's Current Ratio falls into.



CSPC Pharmaceutical Group Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

CSPC Pharmaceutical Group's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=3434.794/1307.725
=2.63

CSPC Pharmaceutical Group's Current Ratio for the quarter that ended in Jun. 2024 is calculated as

Current Ratio (Q: Jun. 2024 )=Total Current Assets (Q: Jun. 2024 )/Total Current Liabilities (Q: Jun. 2024 )
=3389.134/1336.292
=2.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CSPC Pharmaceutical Group  (STU:CVG) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


CSPC Pharmaceutical Group Current Ratio Related Terms

Thank you for viewing the detailed overview of CSPC Pharmaceutical Group's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CSPC Pharmaceutical Group Business Description

Traded in Other Exchanges
Address
No. 226 Huanghe Street, Hebei Province, Shijiazhuang, CHN, 050035
CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C, antibiotics, and a caffeine series.